Home Tags Antibody-drug Conjugates

Tag: Antibody-drug Conjugates

Photo: San Deigo Bay from Harbor Drive, San Diego, CA, USA. Photo Courtesy: This photo has been released into the public domain by its author, Jon Sullivan. This applies worldwide.

From First-in-Human to Post-Commercial: ADC Reference Materials and Specifications

The 2019 World ADC conference in San Diego, CA, held October 8 – 11, 2019, started with a day of 9 interactive workshops on...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

Confocal Microscopy and Imaging Flow Cytometry – Tools for Selection of...

Research articleAbstract Antibody-drug Conjugates (ADCs) are a growing class of targeted anti-cancer therapies, that combine the specific binding of an antibody with the toxic effects...

ASCO 2019 ADC Presentation Guide

We have created the following guide to all presentations related to ADCs for the upcoming ASCO Annual Meeting 2019 taking place at the McCormick...
Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...
What are Antibody-drug Conjugates?

What are Antibody-drug Conjugates?

Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly...

Emerging Trends in Single-Use Technology in the Manufacturing of Antibody-Drug...

Single-use technology, designed for the manufacturing of biopharmaceutical products, has made major inroads over the last 30 years. First introduced in the late 1970s...
Featured Image: Lonza, Visp, Switzerland. Courtesy: © 2010 - 2018 Lonza, Visp, Switzerland. Used with permission.

Lonza Expands Manufacturing Capacity for ADC Payloads

Lonza, a specialty contract development and manufacturing (CDMO) partner to the biopharma industry, will add new highly potent API (HPAPI) manufacturing suites at its...

WuXi Biologics Starts Construction of a State-of-the-Art R&D and Manufacturing Center...

WuXi Biologics, a Hong Kong-listed, open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has started the construction of...

The Scripps Research Institute Receive Five-year Grant from the National Cancer...

Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute (TSRI) , has been awarded a $2.875 million, five-year grant...

The Expanding Field of Antibody-Drug Conjugates

Antibody-drug conjugates or ADCs have emerged as a powerful and strategy tool in the targeted treatment of cancer.  These relatively novel agents combine the...